Treating cardiovascular disease by selectively eliminating senescent cells
Remi-Martin Laberge, San Francisco, CA (US); Judith Campisi, Berkeley, CA (US); Albert Davalos, San Rafael, CA (US); Marco Demaria, Groningen (NL); Nathaniel David, Brisbane, CA (US); Jan M. A. van Deursen, Rochester, MN (US); Darren J. Baker, Rochester, MN (US); and Bennett G. Childs, Rochester, MN (US)
Assigned to Mayo Foundation for Medical Education and Research, Rochester, MN (US); Unity Biotechnology, Inc., Brisbane, CA (US); and Buck Institute for Research on Aging, Novato, CA (US)
Filed by Buck Institute for Research on Aging, Novato, CA (US); Unity Biotechnology, Inc., South San Francisco, CA (US); and Mayo Foundation for Medical Education and Research, Rochester, MN (US)
Filed on Dec. 7, 2020, as Appl. No. 17/114,376.
Application 17/114,376 is a continuation of application No. 16/508,119, filed on Jul. 10, 2019, abandoned.
Application 16/508,119 is a continuation of application No. 15/950,965, filed on Apr. 11, 2018, granted, now 10,413,542.
Application 15/950,965 is a continuation of application No. 15/114,762, granted, now 9,993,472, issued on Jun. 12, 2018, previously published as PCT/US2015/013387, filed on Jan. 28, 2015.
Claims priority of provisional application 62/061,627, filed on Oct. 8, 2014.
Claims priority of provisional application 62/061,629, filed on Oct. 8, 2014.
Claims priority of provisional application 62/057,820, filed on Sep. 30, 2014.
Claims priority of provisional application 62/057,825, filed on Sep. 30, 2014.
Claims priority of provisional application 62/057,828, filed on Sep. 30, 2014.
Claims priority of provisional application 62/044,664, filed on Sep. 2, 2014.
Claims priority of provisional application 62/042,708, filed on Aug. 27, 2014.
Claims priority of provisional application 62/002,709, filed on May 23, 2014.
Claims priority of provisional application 61/979,911, filed on Apr. 15, 2014.
Claims priority of provisional application 61/932,704, filed on Jan. 28, 2014.
Claims priority of provisional application 61/932,711, filed on Jan. 28, 2014.
Prior Publication US 2021/0169875 A1, Jun. 10, 2021
1. A method of selectively eliminating senescent cells in an atherosclerotic plaque comprising:
administering a senolytic agent that consists essentially of a Bcl-2 and Bcl-xL inhibitor or a Bcl-xL selective inhibitor, wherein the senolytic agent is administered to the senescent cells in the atherosclerotic plaque intermittently, wherein the intermittent administration is a treatment cycle followed by a non-treatment interval.